B2B. Cost -saving technologies for laboratory experiments
We have developed a biophysical method to reduce the cost for antibody experiments in the fields of antibody-antigen, peptide-protein interaction, protein-protein interaction via data science.
This method is innovative in the field of molecular biology and our development team is looking for collaboration with university laboratories, pharmacological companies, manufacturing platforms.
Antibody development cost saving
We can reduce the number of false results in vitro to 87%. Our method will include modification of flexible chains of immunoglobults, stepwise testing of each antibody to antigen, determination of key amino acid residues, range of changes in affinity. Antibody development is the procedure of creating and characterizing an antibody. Development begins with injecting an antigen into a host animal, allowing the immune system to target the it and develop a wide mixture of antibodies.
Therapeutic antibody development
We are raising money to fund academic and research projects focusing on Alzheimer's desaese, cancers, such as breast cancer and metastasis. Since we do not get funding from the government or grants, we have a lack of high-performance equipment and a constant lack of additional staff. The speed of project implementation depends very much on these indicators, since we have to work out alternative types of work, for which we receive payment

Development and testing of new antibodies using our biophysical model can significantly save money on laboratory research

We passionately believe that medicine antibody development shouldn't be done alone - collaboration is essential for antibody-antigen development. That's why we are open for work with other innovators across the health landscape including academic scientists, patient organisations, governments, other bio-pharmaceutical companies and healthcare professionals.
Learn more

Explanation of the biophysical model and Data Science

An antibody (Ab), also known as an immunoglobulin (Ig), is a large, Y-shaped protein produced mainly by plasma cells that is used by the immune system to neutralize pathogens such as pathogenic bacteria and viruses. Antibody development is the procedure of creating and characterizing an antibody. Below is a diagram of the biophysical model developed by us, which allows us to determine various parameters of the physical interaction of molecules and thus predict the change in the affinity and stability of the molecular complex thereby reducing the amount of costs for the experiment, increasing its informativeness

Our group developed an innovative method in biology for antibody-antigen development

Innovations, B2B, cancer, antibody, datascience, free download, breast cancer, breast cancer awareness
During the first half of the 20th century, a series of scientific discoveries resolved that antibody-mediated immunity is the cornerstone of the specific immune response. Since their first use as immunolabeling research tools in the early 1970s, antibody technologies have vastly improved, and antibodies have become critical tools for most areas of life science research. The basic principle of any immunochemical technique is that a specific antibody will combine with its specific antigen to generate an exclusive antibody-antigen complex.
Our group has developed an innovative research technique for such a complex using Data Science

Development of therapeutic antibodies for the treatment. Antibody development is a multi-faceted process and an experiment in itself. To assist in generating an immune response towards your antigen. With a unique range of antibody generation platforms, we offer custom monoclonal antibody development to accelerate your research and development.
Procedure for finding suitable immunoglobulins
Innovations, B2B, cancer, antibody, datascience, free download, breast cancer, breast cancer awareness
1.Determination of three-dimensional complex of the target protein with antibody flexible chain, which is subject to further modification. This should be at least one file with the extension of the PDB obtained by the method of X-ray diffraction analysis.
2.To control the received data, you can choose either of two options:
- you can use the additional structure of the PDB of antibody-antigen.
-take advantage of previously available data on the mutations performed, alanine scanning of one of the participants of the antibody-antigen complex

3.Our experts check files, adapt them for computational manipulations using Soft Development and Data Science.
4. Our specialists perform the necessary calculations: obtain data, numerically calculate the results in the form of graphs and diagrams, determine
-key amino acid residues of antibody,
-interaction energies of antibody-antigen complex,
-changes in affinity and stability of antibody-antigen complex,
-change in entropy for each replacement of the amino acid residue in the flexible chain of immunoglobulin.
5. Performing a verification series of calculations in accordance with paragraph 2
Innovations, B2B, cancer, antibody, datascience, free download, breast cancer, breast cancer awareness
Innovations, B2B, cancer, antibody, datascience, free download, breast cancer, breast cancer awareness
You can greatly help the project by taking a survey and sharing information
You can leave your feedback, share information and ask a question through the feedback form.
Vote for the item that best suits you.
Are you interested in reducing the cost and increasing the information content of the experiment?
Your vote has been accepted. Thank you for participating!
You can leave a comment by choosing several options or send your message
Or you can choose the most suits for you
Choose the right option

Mutations in EGFR family

Our team is developing antibodies for 18 forms mutant EGFR proteins. Our method is molecularly selective, targeting certain oncogenic molecules, namely the EGFR family of tyrosine kinases, which occupy a significant share in the causes of oncogenic diseases. The diagram shows the percentage of mutations in proteins of the EGFR family in non-small cell lung cancer.

Sign up to our newsletter

Get a selection of useful weekly articles
Made on